Featured Post from ChristianaCare

Statement from Dr. Eric Kmiec About Expected FDA Approval for CRISPR-Driven Treatment for Sickle Cell Disease

Dec 7, 2023

2 min

Eric Kmiec, Ph.D

Below is a statement from Eric Kmiec, Ph.D., founder and executive director, ChristinaCare Gene Editing Institute, regarding the expected approval by the Food and Drug Administration of exa-cel (Casgevy), the CRISPR-driven treatment for sickle cell disease and betta thalassemia. If you wish to interview Dr. Kmiec, please contact Mak Sisson, Makenzie.sisson@christinacare.org,302-623-5306 or Anna Chen, achen@burness.com, 215-262-7670.


“As scientists, the fact that we have arrived at a potential curative treatment for sickle cell disease in a relatively brief period is a testament to the power of resolute researchers in this field who have never stopped. And the FDA’s expected approval comes with many firsts. For the first time we have what appears to be a safe and curative treatment for one of the most painful diseases that cuts life short. And it is remarkable that finally we are focusing on the Black population first, who are most affected by this disease. This priority is long, long overdue.



The challenge, however, is the very people we want to help may not be able to get access to or afford the million-dollar treatment and the length of time it will take to be treated — weeks and weeks in the hospital. The numbers of people who can be treated are limited. We must work with the health care industry and pharmaceutical companies who will market produce and deliver the treatments to make sure that all people can get access. What can they do to make treatments more affordable and more available? What can they do to support continued research to assess the long-term effects this treatment may have? And how can we make this easier to deliver?


As important as it is to have developed this new treatment, right now we must do our best to communicate well to the public what new findings like this mean. Take the time to explain it all. It cannot be oversold. We must make the communication about this first CRISPR-driven treatment as important as the science itself.”


Eric B. Kmiec, Ph.D., is the founder and executive director of the Gene Editing Institute at ChristianaCare. He is also co-founder and chief scientific officer of CorriXR Therapeutics. Widely recognized for his pioneering work in the fields of molecular medicine and gene editing, Dr. Kmiec has developed CRISPR based genetic therapies for Sickle Cell Disease and Non-Small Cell Lung Cancer. He is Editor-in-Chief of the journal, Gene and Genome Editing.



Connect with:
Eric Kmiec, Ph.D

Eric Kmiec, Ph.D

Executive Director and Chief Scientific Officer, The Gene Editing Institute

Dr. Kmiec, a pioneer in the field, has achieved several ground-breaking firsts in CRISPR gene editing.

Gene EditingBiomedical ResearchMolecular Medicine

You might also like...

Check out some other posts from ChristianaCare

2 min

Forbes Ranks ChristianaCare Among America’s Best Employers for Women in 2024

ChristianaCare has been recognized as one of America’s Best Employers for Women by Forbes for 2024, marking the first time the company has received this prestigious recognition. In a survey of 150,000 women working for companies of at least 1,000 employees in the U.S., ChristianaCare ranked 150 on the list of 600 employers that were recognized. “This important recognition is a testament to our culture and the remarkable women who have chosen to build meaningful careers at ChristianaCare,” said Chris Cowan, MEd, FABC, ChristianaCare’s Chief Human Resources Officer. “Empowering women to succeed is integral to our culture and strengthens our organization. Together, we’ll continue to advance equity and inclusion in the workplace while transforming health and clinical care.” Forbes partnered with market research firm Statista, which surveyed employees on various aspects such as workplace environment, growth opportunities, compensation, diversity, parental leave, schedule flexibility and family assistance. ChristianaCare continues to cultivate a strong, inclusive, and diverse culture for women inside and outside the company by investing in professional development through its Women’s Employee Network (WEN) and providing a comprehensive benefits package that includes various flexible leave options for employees, including at least 12 weeks of paid parental leave. “Receiving this recognition from Forbes is an honor,” said Pamela Ridgeway, MBA, MA, SPHR, chief diversity officer and vice president of Talent and Acquisition at ChristianaCare. “In addition to offering workplace benefits such as paid maternity and paternity leave, ChristianaCare is firmly committed to empowering and advancing talented individuals within the workplace. Receiving this award for the first time signifies our unwavering dedication to ensuring that every individual has a voice and feels truly valued within our organization.” The Forbes recognition follows other national recognitions of ChristianaCare’s commitment to an inclusive workplace. Earlier this year, Forbes ranked ChristianaCare as one of the best employers for diversity in the U.S. Additionally, Forbes ranked ChristianaCare as the top health care employer for veterans in the United States. Both ChristianaCare’s Wilmington Hospital and Christiana Hospital have been named Leaders in LGBTQIA+ Healthcare Equality since 2012.

2 min

ChristianaCare, Delaware’s Largest Private Employer, Raises Minimum Wage to $16.50 an Hour

ChristianaCare has increased its minimum wage to $16.50 an hour effective July 21, 2024. The new $16.50 per hour minimum wage exceeds federal, Delaware, Maryland, New Jersey and Pennsylvania minimum wage rates. “At ChristianaCare, we are committed to creating health so that people can flourish, and that begins with our caregivers,” said ChristianaCare System Chief Operating Officer Ric Cuming, Ed.D., RN, NEA-BC, FAAN. “By investing in our caregivers and supporting their wellbeing, we support their ability to provide the very best care to our patients." ChristianaCare is the largest private employer in Delaware with nearly 14,000 employees. This is the second time in recent years that ChristianaCare has raised its minimum wage; in 2019, ChristianaCare was among the first health systems in the region to raise its minimum wage to $15/hour. This new increase to ChristianaCare’s minimum wage impacts approximately 850 caregivers who were below or near $16.50/hour. Download "It's important for us to lead by example in paying wages that support the financial wellbeing of our workforce,” said Chris Cowan, MEd, FABC, ChristianaCare’s Chief Human Resources Officer. "Substantially increasing wages is one way we continue to attract and keep top talent at all levels in this highly competitive market. By recognizing the valuable contributions of our caregivers, we can enhance staff retention, boost morale and support an exceptional experience for everyone we serve.” The increase is a part of ChristianaCare’s overall Total Rewards package for its caregivers, which includes a wide variety of benefits and support for caregivers and their families through all stages of life. Learn more about ChristianaCare’s Total Rewards here.

3 min

First in Delaware to Offer MR-Guided Ultrasound for Treatment of Essential and Parkinson’s Tremor

Revolutionary technology gives patients immediate relief from debilitating tremors without the need for invasive surgery. ChristianaCare is the first health care provider in Delaware to offer FDA-approved focused ultrasound treatment for people suffering from essential tremor and Parkinson’s disease. The new option – called MR-guided focused ultrasound – uses sound wave energy to destroy precise areas of brain tissue that is the source of the tremor. No surgical incision or anesthesia is necessary, and many patients experience immediate and significant reduction in tremors, which can make daily activities challenging. Dr. Martello explains that the procedure involves the use of high-frequency sound waves directed with pinpoint precision by magnetic resonance imaging to ablate, or burn, the focal point deep within the brain that is causing tremors. “This minimally invasive technology dramatically improves the lives of patients with essential tremor and tremor-dominant Parkinson’s who haven’t fully responded to traditional treatments,’’ said Justin Martello, M.D., director of the Parkinson’s and Movement Disorders Programs, and Focused Ultrasound Program at ChristianaCare. What is tremor? Tremor is a neurological condition that includes involuntary shaking or trembling movements in one or more parts of the body. It most commonly affects the hands and can make daily tasks such as writing, eating and using a computer or phone extremely difficult. Tremor affects approximately 1% of the population overall and 5% of adults age 60+. It is expected to increasingly impact Delawareans as the state’s population ages. Essential tremor is the most common type of tremor. It can occur at any age but is most common in older adults. Tremor is also the most well-known symptom of Parkinson’s disease. An estimated 1.5 million Americans suffer from Parkinson’s disease, a progressive neurodegenerative disease that affects movement and can also affect speech, balance and cognitive function. A newer, better option for patients who don’t respond to medications The procedure of MR-guided focused ultrasound involves the use of high-frequency sound waves directed with pinpoint precision by magnetic resonance imaging to ablate, or burn, the focal point deep within the brain that is causing tremors. Patients are fitted with a frame affixed to a specialized helmet that combines the focused energy of more than 1,000 high-frequency sonic beams directed through the skull. The treatment does not require cutting through the skull, or radiation, as in gamma knife technology. “Today, there are basically three options for managing tremor,” said Pulak Ray, M.D., of Delaware Neurosurgical Group and associate director of the Focused Ultrasound program. “The first is medication, which is effective and affordable for many patients, but its effectiveness tends to diminish over time. The second is deep-brain stimulation, which is the most invasive and costly treatment option. The newest is MR-guided ultrasound, which tends to be the preferable option for most patients who do not respond well to medication, because it is a simple, non-invasive outpatient procedure that is highly effective, safe and produces instant results.” Benefits of MR-guided Focused Ultrasound MR-guided focused ultrasound reduces tremor immediately, with shorter recovery time, lower risk of side effects and lower associated health care expenses compared to surgical alternatives. This treatment dramatically improves patient experience and quality of life for people with Parkinson’s disease or essential tremor. For many patients, MR-guided ultrasound reduces their dependence on caregivers to assist with activities of daily living. Candidates must first undergo a CT scan to ensure a skull density sufficiently thick to accommodate the procedure. The patient is awake during the procedure and situated within an MRI machine for real-time imaging of the brain. The physician tests the precise location by heating the area, then ensuring the patient is able to control tremors by tracing lines on a spirograph. At that point, the physician then permanently ablates the focal point, usually a sphere a few millimeters in length. “Our team is very excited to bring this technology to Delaware and to open up access to potentially life-changing treatment that until now has required long wait times and significant travel for patients,” said Kim Gannon, M.D., Ph.D., medical director of the comprehensive stroke program and physician executive of Neuroscience Service Line at ChristianaCare. “Many tremor patients have suffered for years or even decades with this debilitating and progressive condition and helping them live a more active and independent lifestyle is extremely rewarding.” MR-guided focused ultrasound is covered by Medicare and most insurance plans.

View all posts
Powered by